查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1998716

前列腺特異性抗原檢測市場機會、成長促進因素、產業趨勢分析及預測（2026-2035年）

Prostate-Specific Antigen Test Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2026 - 2035
出版日期: | 出版商: Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球前列腺特異性抗原檢測市場預計到 2025 年將價值 51 億美元，預計到 2035 年將以 7.1% 的複合年成長率成長至 101 億美元。

前列腺癌發病率的上升、PSA檢測技術的不斷進步以及全球診斷實驗室基礎設施的完善推動了市場擴張。 PSA檢測透過測量前列腺產生的一種蛋白質的水平，有助於早期發現前列腺癌、監測疾病進展和評估治療效果。高靈敏度檢測、自動化免疫檢測系統以及檢測準確性的提升等技術創新，增強了臨床對PSA檢測的信心。 PSA密度、PSA速率和反射性檢測等其他技術也提高了診斷準確性，並促進了其在臨床實踐中的更廣泛應用。業界正在轉向基於風險的篩檢策略，將PSA檢測整合到先進的診斷流程中，以在早期發現和最大限度減少過度診斷之間取得平衡。年齡、種族、家族病史、基準PSA水平和合併症等因素正日益影響檢測決策，使PSA檢測更具針對性和治療意義。

初步篩檢作為廣泛應用的初步篩檢工具，預計到2025年將佔據68%的市場。總PSA、遊離PSA比值和初級篩檢組合通常用於在建議進行侵入性檢查前評估癌症風險。由於這些檢測經濟有效、易於取得且非侵入性，因此有助於臨床醫生對患者進行風險分層，避免不必要的切片檢查，從而支持更安全的臨床決策。

市場範圍
開始年份 2025
預測年份 2026-2035
起始金額 51億美元
預測金額 101億美元
複合年成長率 7.1%

預計到2025年，攝護腺癌篩檢市佔率將達到53.5%，到2035年將達到51億美元。 PSA檢測在早期發現前列腺癌方面繼續發揮著至關重要的作用，尤其是在老齡化社會中，並推動了其在定向篩檢和大規模篩檢計畫中的應用。政府和機構對有組織的篩檢舉措的支持正在減少經濟和後勤方面的障礙，從而進一步提高篩檢率。

預計到2025年，北美前列腺特異性抗原（PSA）檢測市場佔有率將達到36.9%，主要促進因素包括前列腺癌高發病率、男性人口老化以及人們對早期檢測意識的提高。醫院、專科診所和診斷實驗室已將PSA檢測納入常規篩檢計畫。先進的醫療基礎設施，包括一流的檢查室和即時檢測設施，以及對下一代檢測方法的巨額投資，正在推動PSA檢測在該地區快速普及和廣泛應用。

目錄

第1章：調查方法

  • 研究途徑
  • 品質改進計劃
    • GMI人工智慧政策和資料完整性計劃
      • 資訊來源一致性通訊協定
  • 調查過程和可靠性評分
    • 調查過程的組成部分
    • 評分組成部分
  • 數據收集
    • 主要來源部分列表
  • 資料探勘資訊來源
    • 付費資訊來源
      • 區域資訊來源
  • 基本估算和計算方法
    • 每種方法中基準年的計算
  • 預測模型
    • 量化市場影響分析
      • 生長參數對預測的數學影響
  • 關於調查透明度的補充信息
    • 資訊來源歸屬框架
    • 品質保證指標
    • 對信任的承諾

第2章執行摘要

第3章業界考察

  • 產業生態系分析
  • 影響產業的因素
    • 成長促進因素
      • 攝護腺癌發生率增加
      • 個人化醫療和預防性診斷的普及
      • 診斷檢測和就地檢驗。
      • 提高對早期檢測和篩檢的認知
    • 產業潛在風險與挑戰
      • 先進的PSA檢測技術高成本
      • 特異性低和假陽性導致的過度診斷
    • 市場機遇
      • 開發下一代多標記診斷平台
      • 家庭和分散式檢查解決方案的成長
  • 成長潛力分析
  • 監理情勢
    • 北美洲
    • 歐洲
    • 亞太地區
  • 科技趨勢
    • 當前技術趨勢
    • 新興技術
  • 救贖方案
  • 未來市場趨勢
  • 2025年價格分析
  • 波特五力分析
  • PESTEL 分析
  • 客戶洞察
  • Start-Ups場景
  • 投資環境
  • 差距分析

第4章 競爭情勢

  • 介紹
  • 企業矩陣分析
  • 企業市佔率分析
    • 世界
    • 北美洲
    • 歐洲
    • 亞太地區
  • 競爭定位矩陣
  • 主要市場公司的競爭分析
  • 主要進展
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 業務拓展計劃

第5章 市場估價與預測：依產品分類，2022-2035年

  • 初步檢查
    • 總攝護腺特異性抗原檢測
    • 聯合前列腺特異性抗原檢測
    • 遊離前列腺特異性抗原檢測
  • 確認性試驗
    • 切片檢查
    • 經直腸超音波檢查
    • PCA3 測試

第6章 市場估計與預測：依應用領域分類，2022-2035年

  • 攝護腺癌篩檢
  • 前列腺癌的後續觀察

第7章 市場估計與預測：依最終用途分類，2022-2035年

  • 醫院
  • 診斷中心
  • 專科診所
  • 其他最終用戶

第8章 市場估計與預測：依地區分類，2022-2035年

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第9章：公司簡介

  • Abbott
  • AdvaCare Pharma
  • Beckman Coulter
  • BIOMERIEUX
  • CTK Biotech
  • DiaSorin
  • Fujirebio
  • Intec
  • KOELIS
  • Labcorp
  • mdxhealth
  • Myriad Genetics
  • OPKO Health
  • Roche
  • SIEMENS Healthineers
簡介目錄
Product Code: 7136

The Global Prostate-Specific Antigen Test Market was valued at USD 5.1 billion in 2025 and is estimated to grow at a CAGR of 7.1% to reach USD 10.1 billion by 2035.

The market's expansion is fueled by the increasing prevalence of prostate cancer, ongoing technological advancements in PSA testing, and the growth of diagnostic laboratory infrastructure worldwide. PSA tests measure the level of a protein produced by the prostate gland, aiding in the early detection of prostate cancer, monitoring disease progression, and assessing treatment outcomes. Technological innovations, such as high-sensitivity assays, automated immunoassay systems, and improved test accuracy, have strengthened clinical confidence in PSA testing. Additional methods, including PSA density, PSA velocity, and reflex testing, enhance diagnostic precision, supporting broader clinical adoption. The industry is moving toward risk-based screening strategies, integrating PSA testing with advanced diagnostic workflows to balance early detection with minimizing overdiagnosis. Factors such as age, ethnicity, family history, baseline PSA levels, and comorbidities increasingly guide testing decisions, making PSA testing more targeted and therapeutically relevant.

The preliminary tests segment held 68% share in 2025 owing to its widespread use as an initial screening tool. Total PSA, free PSA ratio, and first-line screening panels are commonly employed to evaluate cancer risk before recommending invasive procedures. These tests are cost-effective, accessible, and non-invasive, helping clinicians stratify patients and avoid unnecessary biopsies, thereby supporting safer clinical decisions.

Market Scope
Start Year2025
Forecast Year2026-2035
Start Value$5.1 Billion
Forecast Value$10.1 Billion
CAGR7.1%

The prostate cancer screening segment held a 53.5% share in 2025 and is projected to reach USD 5.1 billion through 2035. PSA testing continues to play a crucial role in early detection, particularly in aging populations, driving its adoption in both targeted and population-based screening programs. Government and institutional support in organized screening initiatives reduces financial and logistical barriers, further increasing test uptake.

North America Prostate-Specific Antigen Test Market accounted for 36.9% share in 2025, driven by the high incidence of prostate cancer, an aging male population, and strong awareness of early detection. Hospitals, specialty clinics, and diagnostic laboratories routinely incorporate PSA testing into standard screening programs. Advanced healthcare infrastructure, including state-of-the-art laboratories and point-of-care facilities, along with high investment in next-generation assays, facilitates rapid adoption and widespread availability of PSA tests in the region.

Key players in the Global Prostate-Specific Antigen Test Market include Abbott, AdvaCare Pharma, Beckman Coulter, BIOMERIEUX, CTK Biotech, DiaSorin, Fujirebio, Intec, KOELIS, Labcorp, mdxhealth, Myriad Genetics, OPKO Health, Roche, and SIEMENS Healthineers. Companies in the Global Prostate-Specific Antigen Test Market are employing multiple strategies to strengthen their market foothold. They focus on product innovation, developing highly sensitive, automated, and user-friendly assays for accurate early detection and monitoring. Strategic partnerships with hospitals, diagnostic labs, and healthcare networks expand distribution and adoption. Investment in R&D ensures next-generation technologies, improved assay performance, and regulatory compliance. Geographic expansion into high-growth regions increases market penetration, while marketing campaigns emphasize accuracy, reliability, and clinical relevance. Firms also provide training and technical support to laboratories and clinicians to enhance usage and build long-term customer loyalty, thereby solidifying their competitive positioning.

Table of Contents

Chapter 1 Research Methodology

  • 1.1 Research approach
  • 1.2 Quality commitments
    • 1.2.1 GMI AI policy & data integrity commitment
      • 1.2.1.1 Source consistency protocol
  • 1.3 Research trail & confidence scoring
    • 1.3.1 Research trail components
    • 1.3.2 Scoring components
  • 1.4 Data collection
    • 1.4.1 Partial list of primary sources
  • 1.5 Data mining sources
    • 1.5.1 Paid sources
      • 1.5.1.1 Sources, by region
  • 1.6 Base estimates and calculations
    • 1.6.1 Base year calculation for any one approach
  • 1.7 Forecast model
    • 1.7.1 Quantified market impact analysis
      • 1.7.1.1 Mathematical impact of growth parameters on forecast
  • 1.8 Research transparency addendum
    • 1.8.1 Source attribution framework
    • 1.8.2 Quality assurance metrics
    • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Product trends
    • 2.2.3 Application trends
    • 2.2.4 End use trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence of prostate cancer
      • 3.2.1.2 Adoption of personalized healthcare and preventive diagnostics
      • 3.2.1.3 Technological advancements in diagnostic assays and point-of-care testing
      • 3.2.1.4 Rising awareness of early detection and screening
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of advanced PSA testing technologies
      • 3.2.2.2 Limited specificity and false positives leading to overdiagnosis
    • 3.2.3 Market opportunities
      • 3.2.3.1 Development of next-generation and multi-marker diagnostic platforms
      • 3.2.3.2 Growth in home-based and decentralized testing solutions
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Technology landscape
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Reimbursement scenario
  • 3.7 Future market trends
  • 3.8 Pricing analysis, 2025
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis
  • 3.11 Customer insights
  • 3.12 Start-up scenarios
  • 3.13 Investment landscape
  • 3.14 Gap analysis

Chapter 4 Competitive Landscape, 2025

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Company market share analysis
    • 4.3.1 Global
    • 4.3.2 North America
    • 4.3.3 Europe
    • 4.3.4 Asia Pacific
  • 4.4 Competitive positioning matrix
  • 4.5 Competitive analysis of major market players
  • 4.6 Key developments
    • 4.6.1 Mergers & acquisitions
    • 4.6.2 Partnerships & collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Product, 2022 - 2035 ($ Mn)

  • 5.1 Key trends
  • 5.2 Preliminary tests
    • 5.2.1 Total prostate specific antigen test
    • 5.2.2 Complex prostate specific antigen test
    • 5.2.3 Free prostate specific antigen test
  • 5.3 Confirmatory tests
    • 5.3.1 Biopsy
    • 5.3.2 Trans-rectal ultrasound
    • 5.3.3 PCA3Test

Chapter 6 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

  • 6.1 Key trends
  • 6.2 Prostate cancer screening
  • 6.3 Prostate cancer monitoring

Chapter 7 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

  • 7.1 Key trends
  • 7.2 Hospitals
  • 7.3 Diagnostic centers
  • 7.4 Specialty clinics
  • 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE

Chapter 9 Company Profiles

  • 9.1 Abbott
  • 9.2 AdvaCare Pharma
  • 9.3 Beckman Coulter
  • 9.4 BIOMERIEUX
  • 9.5 CTK Biotech
  • 9.6 DiaSorin
  • 9.7 Fujirebio
  • 9.8 Intec
  • 9.9 KOELIS
  • 9.10 Labcorp
  • 9.11 mdxhealth
  • 9.12 Myriad Genetics
  • 9.13 OPKO Health
  • 9.14 Roche
  • 9.15 SIEMENS Healthineers